Hosted on MSN
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback